For the next two weeks, Fixing Healthcare hosts Jeremy Corr and Dr. Robert Pearl will be replaying past episodes of Diving Deep while Dr. Pearl travels and keynotes events around the world. But these aren’t random reruns. They were selected for a reason: to highlight just how quickly technology is advancing and how slowly healthcare is adapting.

This week’s flashback revisits a July 2024 conversation recorded shortly after OpenAI released GPT-4o, a major leap forward in generative AI at the time. Less than two years later, the pace of change is striking. Capabilities that once felt groundbreaking now seem primitive compared to what today’s AI tools can accomplish for patients, physicians and healthcare organizations.

At the same time, the episode’s broader themes remain remarkably current. Dr. Pearl and Jeremy discuss the future role of generative AI in medicine, how these tools could improve diagnosis and patient monitoring and why healthcare institutions often struggle to embrace transformative technology quickly.

The episode also examines another issue that remains unresolved today: the high cost of GLP-1 medications like Wegovy and Ozempic. Dr. Pearl explains why these highly effective obesity treatments remain financially out of reach for many Americans despite growing demand and expanding clinical use.

Revisiting this conversation now offers a useful reminder: technology can advance extraordinarily fast, but healthcare systems, incentives and policies often lag far behind.

Helpful links: 

* * *

Dr. Robert Pearl is the author of “ChatGPT, MD: How AI-Empowered Patients & Doctors Can Take Back Control of American Medicine.” Fixing Healthcare is a co-production of Dr. Robert Pearl and Jeremy Corr. Subscribe to the show via Apple, Spotify or wherever you find podcasts. Join the conversation or suggest a guest by following the show on X and LinkedIn.

The post FHC #214: Revisiting GLP-1 prices and ChatGPT’s early leap forward appeared first on Fixing Healthcare.